English
简体中文
Total: £ 56.28
Published Date: 2026-03-24 | Pages: 114 | Tables: 119 | Pharma & Healthcare
The global Inflammatory Bowel Disease Drugs market was valued at US$ 22670 million in 2025 and is anticipated to reach US$ 31230 million by 2032, at a CAGR of 4.8% from 2026 to 2032.
Inflammatory Bowel Disease Drugs refer to pharmaceutical therapies used to treat and manage inflammatory bowel disease (IBD), primarily including Crohn’s disease and ulcerative colitis, which are chronic inflammatory disorders of the gastrointestinal tract. These drugs work by regulating immune responses, suppressing inflammatory cytokines, and promoting the healing of intestinal mucosa, thereby relieving symptoms and controlling disease progression. Common therapeutic categories include aminosalicylates, corticosteroids, immunosuppressants, biologic therapies, and more recently developed targeted small-molecule drugs. With advances in immunology and biopharmaceutical technologies, innovative therapies targeting specific inflammatory pathways and immune mechanisms are increasingly being developed. As a result, the treatment paradigm for inflammatory bowel disease is gradually shifting from traditional anti-inflammatory therapy toward precision medicine and personalized treatment strategies. These drugs play a critical role in symptom management, maintenance of remission, and prevention of disease relapse, making them a key component of gastrointestinal disease therapeutics.The average gross profit margin of this product is 55%.
With the evolving prevalence of gastrointestinal disorders and increasing public health awareness, inflammatory bowel disease has attracted growing attention from healthcare institutions and pharmaceutical companies. Medical research suggests that genetic factors, immune dysregulation, and lifestyle changes may contribute to the development of the disease, leading to a growing patient population and increased demand for treatment drugs. Meanwhile, advancements in biologics and targeted therapies have provided more precise and effective treatment options for inflammatory bowel disease. Pharmaceutical companies continue to invest heavily in innovative drug development and introduce therapies targeting specific immune pathways, driving technological progress and market expansion in the industry.
Despite strong growth, the inflammatory bowel disease drug market faces several challenges. IBD is a complex immune-mediated disorder with significant variability among patients, making drug development and treatment strategies more complicated. In addition, the development cycle for innovative biologics and targeted drugs is relatively long, and strict clinical trial and regulatory approval requirements lead to high development costs. Some patients may also develop drug resistance or experience adverse effects during long-term treatment, which raises additional concerns regarding safety and long-term therapeutic effectiveness.
Downstream demand for inflammatory bowel disease drugs mainly comes from hospitals, gastroenterology specialty clinics, and chronic disease management programs. As the concept of long-term disease management becomes more widely adopted, both patients and healthcare providers are placing greater emphasis on maintenance therapy and continuous monitoring, resulting in sustained medication demand. Precision medicine and personalized treatment approaches are also being increasingly applied in gastrointestinal disease management, with physicians considering drug targets, patient conditions, and treatment responses when selecting therapeutic strategies. Furthermore, the development of digital healthcare platforms and telemedicine services is providing additional support for long-term patient management.
The upstream supply chain of inflammatory bowel disease drugs primarily involves active pharmaceutical ingredients, chemical synthesis materials, biotechnological production platforms, and pharmaceutical excipients. Small-molecule drugs are typically produced through chemical synthesis processes, while biologic therapies rely on cell culture, protein expression, and purification technologies. In addition, excipients such as stabilizers, buffers, and drug carrier materials play essential roles in pharmaceutical formulations. With the advancement of biotechnology and pharmaceutical engineering, improvements in upstream production processes and raw material supply systems are providing strong support for the research, development, and large-scale manufacturing of inflammatory bowel disease drugs.
This report delivers a comprehensive overview of the global Inflammatory Bowel Disease Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Inflammatory Bowel Disease Drugs. The Inflammatory Bowel Disease Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Inflammatory Bowel Disease Drugs market comprehensively. Regional market sizes by Type, by Application, by End User, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Inflammatory Bowel Disease Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AbbVie
Johnson & Johnson
Takeda Pharmaceutical Company
Pfizer
Eli Lilly and Company
Bristol Myers Squibb
Roche
Amgen
Gilead Sciences
UCB
Novartis
Merck & Co.
Sanofi
Biogen
Samsung Bioepis
Segment by Type
Biologic Drugs
Small Molecules
Aminosalicylates
Corticosteroids
Segment by End User
Oral Drugs
Subcutaneous Injection
Intravenous Infusion
Rectal Therapy
Segment by Application
Crohn Disease
Ulcerative Colitis
Indeterminate Colitis
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by End User, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Inflammatory Bowel Disease Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inflammatory Bowel Disease Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Biologic Drugs
1.2.3 Small Molecules
1.2.4 Aminosalicylates
1.2.5 Corticosteroids
1.3 Market by End User
1.3.1 Global Inflammatory Bowel Disease Drugs Market Size Growth Rate by End User: 2021 vs 2025 vs 2032
1.3.2 Oral Drugs
1.3.3 Subcutaneous Injection
1.3.4 Intravenous Infusion
1.3.5 Rectal Therapy
1.4 Market by Application
1.4.1 Global Inflammatory Bowel Disease Drugs Market Growth by Application: 2021 vs 2025 vs 2032
1.4.2 Crohn Disease
1.4.3 Ulcerative Colitis
1.4.4 Indeterminate Colitis
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Inflammatory Bowel Disease Drugs Market Perspective (2021–2032)
2.2 Global Inflammatory Bowel Disease Drugs Growth Trends by Region
2.2.1 Global Inflammatory Bowel Disease Drugs Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Inflammatory Bowel Disease Drugs Historic Market Size by Region (2021–2026)
2.2.3 Inflammatory Bowel Disease Drugs Forecasted Market Size by Region (2027–2032)
2.3 Inflammatory Bowel Disease Drugs Market Dynamics
2.3.1 Inflammatory Bowel Disease Drugs Industry Trends
2.3.2 Inflammatory Bowel Disease Drugs Market Drivers
2.3.3 Inflammatory Bowel Disease Drugs Market Challenges
2.3.4 Inflammatory Bowel Disease Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inflammatory Bowel Disease Drugs Players by Revenue
3.1.1 Global Top Inflammatory Bowel Disease Drugs Players by Revenue (2021–2026)
3.1.2 Global Inflammatory Bowel Disease Drugs Revenue Market Share by Players (2021–2026)
3.2 Global Top Inflammatory Bowel Disease Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Inflammatory Bowel Disease Drugs Revenue
3.4 Global Inflammatory Bowel Disease Drugs Market Concentration Ratio
3.4.1 Global Inflammatory Bowel Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inflammatory Bowel Disease Drugs Revenue in 2025
3.5 Global Key Players of Inflammatory Bowel Disease Drugs Head Offices and Areas Served
3.6 Global Key Players of Inflammatory Bowel Disease Drugs, Products and Applications
3.7 Global Key Players of Inflammatory Bowel Disease Drugs, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Inflammatory Bowel Disease Drugs Breakdown Data by Type
4.1 Global Inflammatory Bowel Disease Drugs Historic Market Size by Type (2021–2026)
4.2 Global Inflammatory Bowel Disease Drugs Forecasted Market Size by Type (2027–2032)
5 Inflammatory Bowel Disease Drugs Breakdown Data by Application
5.1 Global Inflammatory Bowel Disease Drugs Historic Market Size by Application (2021–2026)
5.2 Global Inflammatory Bowel Disease Drugs Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Inflammatory Bowel Disease Drugs Market Size (2021–2032)
6.2 North America Inflammatory Bowel Disease Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Inflammatory Bowel Disease Drugs Market Size by Country (2021–2026)
6.4 North America Inflammatory Bowel Disease Drugs Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Inflammatory Bowel Disease Drugs Market Size (2021–2032)
7.2 Europe Inflammatory Bowel Disease Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Inflammatory Bowel Disease Drugs Market Size by Country (2021–2026)
7.4 Europe Inflammatory Bowel Disease Drugs Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Inflammatory Bowel Disease Drugs Market Size (2021–2032)
8.2 Asia-Pacific Inflammatory Bowel Disease Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Inflammatory Bowel Disease Drugs Market Size by Region (2021–2026)
8.4 Asia-Pacific Inflammatory Bowel Disease Drugs Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Inflammatory Bowel Disease Drugs Market Size (2021–2032)
9.2 Latin America Inflammatory Bowel Disease Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Inflammatory Bowel Disease Drugs Market Size by Country (2021–2026)
9.4 Latin America Inflammatory Bowel Disease Drugs Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inflammatory Bowel Disease Drugs Market Size (2021–2032)
10.2 Middle East & Africa Inflammatory Bowel Disease Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Inflammatory Bowel Disease Drugs Market Size by Country (2021–2026)
10.4 Middle East & Africa Inflammatory Bowel Disease Drugs Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Inflammatory Bowel Disease Drugs Introduction
11.1.4 AbbVie Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.1.5 AbbVie Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Inflammatory Bowel Disease Drugs Introduction
11.2.4 Johnson & Johnson Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.2.5 Johnson & Johnson Recent Development
11.3 Takeda Pharmaceutical Company
11.3.1 Takeda Pharmaceutical Company Company Details
11.3.2 Takeda Pharmaceutical Company Business Overview
11.3.3 Takeda Pharmaceutical Company Inflammatory Bowel Disease Drugs Introduction
11.3.4 Takeda Pharmaceutical Company Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.3.5 Takeda Pharmaceutical Company Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Inflammatory Bowel Disease Drugs Introduction
11.4.4 Pfizer Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.4.5 Pfizer Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Inflammatory Bowel Disease Drugs Introduction
11.5.4 Eli Lilly and Company Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.5.5 Eli Lilly and Company Recent Development
11.6 Bristol Myers Squibb
11.6.1 Bristol Myers Squibb Company Details
11.6.2 Bristol Myers Squibb Business Overview
11.6.3 Bristol Myers Squibb Inflammatory Bowel Disease Drugs Introduction
11.6.4 Bristol Myers Squibb Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.6.5 Bristol Myers Squibb Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Inflammatory Bowel Disease Drugs Introduction
11.7.4 Roche Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.7.5 Roche Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen Inflammatory Bowel Disease Drugs Introduction
11.8.4 Amgen Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.8.5 Amgen Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Inflammatory Bowel Disease Drugs Introduction
11.9.4 Gilead Sciences Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.9.5 Gilead Sciences Recent Development
11.10 UCB
11.10.1 UCB Company Details
11.10.2 UCB Business Overview
11.10.3 UCB Inflammatory Bowel Disease Drugs Introduction
11.10.4 UCB Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.10.5 UCB Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Inflammatory Bowel Disease Drugs Introduction
11.11.4 Novartis Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.11.5 Novartis Recent Development
11.12 Merck & Co.
11.12.1 Merck & Co. Company Details
11.12.2 Merck & Co. Business Overview
11.12.3 Merck & Co. Inflammatory Bowel Disease Drugs Introduction
11.12.4 Merck & Co. Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.12.5 Merck & Co. Recent Development
11.13 Sanofi
11.13.1 Sanofi Company Details
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Inflammatory Bowel Disease Drugs Introduction
11.13.4 Sanofi Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.13.5 Sanofi Recent Development
11.14 Biogen
11.14.1 Biogen Company Details
11.14.2 Biogen Business Overview
11.14.3 Biogen Inflammatory Bowel Disease Drugs Introduction
11.14.4 Biogen Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.14.5 Biogen Recent Development
11.15 Samsung Bioepis
11.15.1 Samsung Bioepis Company Details
11.15.2 Samsung Bioepis Business Overview
11.15.3 Samsung Bioepis Inflammatory Bowel Disease Drugs Introduction
11.15.4 Samsung Bioepis Revenue in Inflammatory Bowel Disease Drugs Business (2021–2026)
11.15.5 Samsung Bioepis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Inflammatory Bowel Disease Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Biologic Drugs
Table 3. Key Players of Small Molecules
Table 4. Key Players of Aminosalicylates
Table 5. Key Players of Corticosteroids
Table 6. Global Inflammatory Bowel Disease Drugs Market Size Growth Rate by End User (US$ Million): 2021 vs 2025 vs 2032
Table 7. Key Players of Oral Drugs
Table 8. Key Players of Subcutaneous Injection
Table 9. Key Players of Intravenous Infusion
Table 10. Key Players of Rectal Therapy
Table 11. Key Players of Hospitals
Table 12. Key Players of Clinics
Table 13. Key Players of Retail Pharmacies
Table 14. Key Players of Others
Table 15. Global Inflammatory Bowel Disease Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 16. Global Inflammatory Bowel Disease Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Inflammatory Bowel Disease Drugs Market Size by Region (US$ Million), 2021–2026
Table 18. Global Inflammatory Bowel Disease Drugs Market Share by Region (2021–2026)
Table 19. Global Inflammatory Bowel Disease Drugs Forecasted Market Size by Region (US$ Million), 2027–2032
Table 20. Global Inflammatory Bowel Disease Drugs Market Share by Region (2027–2032)
Table 21. Inflammatory Bowel Disease Drugs Market Trends
Table 22. Inflammatory Bowel Disease Drugs Market Drivers
Table 23. Inflammatory Bowel Disease Drugs Market Challenges
Table 24. Inflammatory Bowel Disease Drugs Market Restraints
Table 25. Global Inflammatory Bowel Disease Drugs Revenue by Players (US$ Million), 2021–2026
Table 26. Global Inflammatory Bowel Disease Drugs Market Share by Players (2021–2026)
Table 27. Global Top Inflammatory Bowel Disease Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Inflammatory Bowel Disease Drugs Revenue, 2025
Table 28. Ranking of Global Top Inflammatory Bowel Disease Drugs Companies by Revenue (US$ Million) in 2025
Table 29. Global 5 Largest Players Market Share by Inflammatory Bowel Disease Drugs Revenue (CR5 and HHI), 2021–2026
Table 30. Global Key Players of Inflammatory Bowel Disease Drugs, Headquarters and Area Served
Table 31. Global Key Players of Inflammatory Bowel Disease Drugs, Products and Applications
Table 32. Global Key Players of Inflammatory Bowel Disease Drugs, Date of General Availability (GA)
Table 33. Mergers and Acquisitions, Expansion Plans
Table 34. Global Inflammatory Bowel Disease Drugs Market Size by Type (US$ Million), 2021–2026
Table 35. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021–2026)
Table 36. Global Inflammatory Bowel Disease Drugs Forecasted Market Size by Type (US$ Million), 2027–2032
Table 37. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2027–2032)
Table 38. Global Inflammatory Bowel Disease Drugs Market Size by Application (US$ Million), 2021–2026
Table 39. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021–2026)
Table 40. Global Inflammatory Bowel Disease Drugs Forecasted Market Size by Application (US$ Million), 2027–2032
Table 41. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2027–2032)
Table 42. North America Inflammatory Bowel Disease Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. North America Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2021–2026
Table 44. North America Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2027–2032
Table 45. Europe Inflammatory Bowel Disease Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Europe Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2021–2026
Table 47. Europe Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2027–2032
Table 48. Asia-Pacific Inflammatory Bowel Disease Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 49. Asia-Pacific Inflammatory Bowel Disease Drugs Market Size by Region (US$ Million), 2021–2026
Table 50. Asia-Pacific Inflammatory Bowel Disease Drugs Market Size by Region (US$ Million), 2027–2032
Table 51. Latin America Inflammatory Bowel Disease Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 52. Latin America Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2021–2026
Table 53. Latin America Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2027–2032
Table 54. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 55. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2021–2026
Table 56. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size by Country (US$ Million), 2027–2032
Table 57. AbbVie Company Details
Table 58. AbbVie Business Overview
Table 59. AbbVie Inflammatory Bowel Disease Drugs Product
Table 60. AbbVie Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 61. AbbVie Recent Development
Table 62. Johnson & Johnson Company Details
Table 63. Johnson & Johnson Business Overview
Table 64. Johnson & Johnson Inflammatory Bowel Disease Drugs Product
Table 65. Johnson & Johnson Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 66. Johnson & Johnson Recent Development
Table 67. Takeda Pharmaceutical Company Company Details
Table 68. Takeda Pharmaceutical Company Business Overview
Table 69. Takeda Pharmaceutical Company Inflammatory Bowel Disease Drugs Product
Table 70. Takeda Pharmaceutical Company Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 71. Takeda Pharmaceutical Company Recent Development
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Inflammatory Bowel Disease Drugs Product
Table 75. Pfizer Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 76. Pfizer Recent Development
Table 77. Eli Lilly and Company Company Details
Table 78. Eli Lilly and Company Business Overview
Table 79. Eli Lilly and Company Inflammatory Bowel Disease Drugs Product
Table 80. Eli Lilly and Company Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 81. Eli Lilly and Company Recent Development
Table 82. Bristol Myers Squibb Company Details
Table 83. Bristol Myers Squibb Business Overview
Table 84. Bristol Myers Squibb Inflammatory Bowel Disease Drugs Product
Table 85. Bristol Myers Squibb Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 86. Bristol Myers Squibb Recent Development
Table 87. Roche Company Details
Table 88. Roche Business Overview
Table 89. Roche Inflammatory Bowel Disease Drugs Product
Table 90. Roche Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 91. Roche Recent Development
Table 92. Amgen Company Details
Table 93. Amgen Business Overview
Table 94. Amgen Inflammatory Bowel Disease Drugs Product
Table 95. Amgen Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 96. Amgen Recent Development
Table 97. Gilead Sciences Company Details
Table 98. Gilead Sciences Business Overview
Table 99. Gilead Sciences Inflammatory Bowel Disease Drugs Product
Table 100. Gilead Sciences Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 101. Gilead Sciences Recent Development
Table 102. UCB Company Details
Table 103. UCB Business Overview
Table 104. UCB Inflammatory Bowel Disease Drugs Product
Table 105. UCB Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 106. UCB Recent Development
Table 107. Novartis Company Details
Table 108. Novartis Business Overview
Table 109. Novartis Inflammatory Bowel Disease Drugs Product
Table 110. Novartis Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 111. Novartis Recent Development
Table 112. Merck & Co. Company Details
Table 113. Merck & Co. Business Overview
Table 114. Merck & Co. Inflammatory Bowel Disease Drugs Product
Table 115. Merck & Co. Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 116. Merck & Co. Recent Development
Table 117. Sanofi Company Details
Table 118. Sanofi Business Overview
Table 119. Sanofi Inflammatory Bowel Disease Drugs Product
Table 120. Sanofi Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 121. Sanofi Recent Development
Table 122. Biogen Company Details
Table 123. Biogen Business Overview
Table 124. Biogen Inflammatory Bowel Disease Drugs Product
Table 125. Biogen Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 126. Biogen Recent Development
Table 127. Samsung Bioepis Company Details
Table 128. Samsung Bioepis Business Overview
Table 129. Samsung Bioepis Inflammatory Bowel Disease Drugs Product
Table 130. Samsung Bioepis Revenue in Inflammatory Bowel Disease Drugs Business (US$ Million), 2021–2026
Table 131. Samsung Bioepis Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
Table 135. Authors List of This Report
List of Figures
Figure 1. Inflammatory Bowel Disease Drugs Picture
Figure 2. Global Inflammatory Bowel Disease Drugs Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Inflammatory Bowel Disease Drugs Market Share by Type: 2025 vs 2032
Figure 4. Biologic Drugs Features
Figure 5. Small Molecules Features
Figure 6. Aminosalicylates Features
Figure 7. Corticosteroids Features
Figure 8. Global Inflammatory Bowel Disease Drugs Market Size Comparison by End User (US$ Million), 2021–2032
Figure 9. Oral Drugs Features
Figure 10. Subcutaneous Injection Features
Figure 11. Intravenous Infusion Features
Figure 12. Rectal Therapy Features
Figure 13. Hospitals Features
Figure 14. Clinics Features
Figure 15. Retail Pharmacies Features
Figure 16. Others Features
Figure 17. Global Inflammatory Bowel Disease Drugs Market Size by Application (US$ Million), 2021–2032
Figure 18. Global Inflammatory Bowel Disease Drugs Market Share by Application: 2025 vs 2032
Figure 19. Crohn Disease Case Studies
Figure 20. Ulcerative Colitis Case Studies
Figure 21. Indeterminate Colitis Case Studies
Figure 22. Inflammatory Bowel Disease Drugs Report Years Considered
Figure 23. Global Inflammatory Bowel Disease Drugs Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 24. Global Inflammatory Bowel Disease Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 25. Global Inflammatory Bowel Disease Drugs Market Share by Region: 2025 vs 2032
Figure 26. Global Inflammatory Bowel Disease Drugs Market Share by Players in 2025
Figure 27. Global Inflammatory Bowel Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 28. The Top 10 and 5 Players Market Share by Inflammatory Bowel Disease Drugs Revenue in 2025
Figure 29. North America Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. North America Inflammatory Bowel Disease Drugs Market Share by Country (2021–2032)
Figure 31. United States Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Canada Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Europe Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Europe Inflammatory Bowel Disease Drugs Market Share by Country (2021–2032)
Figure 35. Germany Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. France Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. U.K. Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Italy Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Russia Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Ireland Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Asia-Pacific Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Asia-Pacific Inflammatory Bowel Disease Drugs Market Share by Region (2021–2032)
Figure 43. China Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Japan Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. South Korea Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Southeast Asia Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. India Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Australia & New Zealand Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Latin America Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Latin America Inflammatory Bowel Disease Drugs Market Share by Country (2021–2032)
Figure 51. Mexico Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Brazil Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Middle East & Africa Inflammatory Bowel Disease Drugs Market Share by Country (2021–2032)
Figure 55. Israel Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 56. Saudi Arabia Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. UAE Inflammatory Bowel Disease Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 58. AbbVie Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 59. Johnson & Johnson Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 60. Takeda Pharmaceutical Company Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 61. Pfizer Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 62. Eli Lilly and Company Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 63. Bristol Myers Squibb Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 64. Roche Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 65. Amgen Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 66. Gilead Sciences Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 67. UCB Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 68. Novartis Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 69. Merck & Co. Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 70. Sanofi Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 71. Biogen Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 72. Samsung Bioepis Revenue Growth Rate in Inflammatory Bowel Disease Drugs Business (2021–2026)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
